Etiket: health

A breakthrough treatment for diabetes could mean the end of daily injections for hundreds of thousands of patients. A new weekly insulin jab, known as Onswik and developed by Eli Lilly, promises to reduce the number of injections needed each year by a staggering 86%. This means that instead of pricking themselves every day, patients might only need to do it once a week. However, there’s a catch: they must wait for approval from the medicines regulator before it can be made available through the NHS.

Currently, around 4.7 million people in the UK are battling diabetes, and approximately 90% of them are dealing with insulin resistance, a condition where the body can’t use insulin effectively. Diabetes UK highlights that around one in four of these individuals takes insulin. Switching to a weekly jab could be a game-changer, especially for those who face challenges with daily injections. This includes elderly people, those with vision problems, limited hand movement, and even individuals with learning disabilities. Can you imagine the relief for someone who struggles with daily routines just to manage their health?

Douglas Twenefour, the head of clinical at Diabetes UK, mentioned that this new treatment could significantly enhance the quality of life for those who need assistance with their injections. It’s essential for people who find it hard to follow the steps involved in daily injections or who simply can’t keep up with their treatment regimen. Helen Knight, the director of medicines evaluation at NICE, echoed these sentiments, stating that the new treatment could represent a significant advancement for diabetes care.

The initial green light for Onswik has come from the National Institute for Health and Care Excellence (NICE), which decides on medications and treatments available on the NHS. But before this treatment can be rolled out, it still needs to be sanctioned by the Medicines and Healthcare products Regulatory Agency (MHRA). Health officials are currently waiting for the MHRA’s decision. It’s worth noting that NICE guidelines apply to the NHS in England, while the NHS in Wales often follows these recommendations. However, Northern Ireland and Scotland have their own review processes, which means the rollout could vary across the UK.

Interestingly, there’s also a troubling trend: more young women in their 20s are being diagnosed with diabetes. This change in demographics raises questions about lifestyle, health education, and the need for effective treatments. Furthermore, the potential for new weight-loss drugs as part of diabetes care opens up yet another avenue for managing this complex condition.

As we look to the future, the question remains: how quickly will this revolutionary treatment be approved? And will it truly make life easier for those living with diabetes? We’ll be keeping a close eye on the developments surrounding this exciting new jab…

Kaynak: Orijinal Haber

The NHS in England and Wales is making waves with the introduction of Teplizumab, the first-ever drug that can delay the onset of type 1 diabetes, a game changer for many families. This immunotherapy treatment could provide individuals diagnosed with the condition an additional three years before they face the relentless daily grind of insulin dependency. Imagine, just three extra years of normalcy! How crucial is that for a child or a loved one? The NHS medicines body calls this decision a “genuinely exciting moment” for patients and their families.

Theo Sebastian-Jenkin, diagnosed with diabetes at a young age, faced severe fatigue and rapid weight loss. His mother, Vicky, reflects on the burden of managing the condition, saying, “It’s something which you can never switch off from.” Just picture a morning routine—preparing breakfast, only to remember that this disease is always lurking. Theo’s parents believe that any medicine capable of delaying the onset could transform the lives of countless other children each year. They’ve seen firsthand how urgent intervention can change lives, especially with family members already on insulin.

Teplizumab doesn’t just buy time; it offers hope. Vicky emphasizes, “The biggest gift Teplizumab gives us is time—just time being a normal kid, living a normal life.” I mean, who wouldn’t want their child to experience the joy of childhood without the constant worry of managing a chronic illness? It’s a leap forward, and for the first time, there’s a treatment that allows those diagnosed early on to savor extra precious moments before the full weight of managing type 1 diabetes hits.

As the conversation around this breakthrough treatment grows, Breakthrough T1D, which funded earlier research leading to the development of Teplizumab, is optimistic about the future. They’re exploring additional immunotherapy treatments with the hope that patients will eventually receive personalized combinations of these drugs, potentially eliminating the need for insulin therapy altogether. Now, that’s a future we can all look forward to!

However, it’s important to note that while this treatment is being rolled out, the guidance from NICE does not automatically extend to Northern Ireland, and in Scotland, the Scottish Medicines Consortium assesses which drugs the NHS should provide. The SMC is expected to offer advice on Teplizumab in early 2027. So, for those in those regions, there’s still a wait ahead.

Have you or someone you know been impacted by diabetes? The community is eager to hear your stories and experiences. As we navigate these developments, it raises the question: what else is on the horizon for diabetes treatments? The journey continues, and we’re here for it!

Kaynak: Orijinal Haber